William Hendriks
Director - PSC Biology BlueRock Therapeutics
Seminars
Wednesday 9th September 2026
Optimizing Donor & Starting‑Line Selection to Enhance iPSC Quality & Reduce Downstream Variability
1:40 pm
- Building multi‑donor and multi‑clone assessment frameworks to prevent over‑reliance on a single source and reduce variability
- Identifying donor‑derived biases: how age, source material, and intrinsic biology predispose iPSCs to certain lineages
- Navigating preclinical ethical and regulatory constraints that can stall animal work or destabilize program timelines
Thursday 10th September 2026
Fireside Chat: Balancing Immune Evasion with Safety Controls to Prevent Oncogenic Outgrowth & Improve Preclinical Risk Predictability
2:00 pm
- Assessing how iPSC‑derived cells may evade or escape immune surveillance, and the implications for uncontrolled proliferation in vivo
- Integrating kill‑switches, regulated elimination systems, and early oncogenicity assays to counter immune‑escape driven safety concerns
- Designing preclinical studies that separate acceptable immune evasion for persistence from high‑risk profiles that could trigger CRS, ICANS or tumor‑like expansion
